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SUMMARY 
 
Biologic therapies are widely used in inflammatory diseases, and they are associated to an 
increased infection risk, especially to granulomatous and intracellular infections such as 
Legionella. A review of the literature revealed 105 cases of Legionella pneumonia in patients 
taking biologic therapies. Sixty-four patients (65.3%) were treated with infliximab, 23 
(23.5%) with adalimumab, 5 (5%) with etanercept and 3 (3%) with rituximab. Seventy-one 
per cent of the patients were treated for rheumatologic diseases and 16% for inflammatory 
bowel diseases. The majority of the patients received one or more concomitant 
immunosuppressive drugs, especially steroids (43%). Overall mortality was 19%. Legionella 
pneumonia might complicate therapy with biologic therapies, especially in patients being 
treated with infliximab or adalimumab given concomitantly with other immunosuppressive 
medications during their first 6 months of treatment. Physicians should be aware of this 
potentially severe association. Early recognition and treatment would likely result in reduced 
morbidity and mortality.  
 
 
 
 
 
 
 
 
 
 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
3 
 
INTRODUCTION 
 
Biologic agents approved for clinical use include tumour necrosis factor alpha inhibitors 
(anti-TNFα) such as etanercept, infliximab, adalimumab, golimumab, and certolizumab 
pegol; the interleukin (IL)-1 receptor antagonist, anakinra; the T-cell costimulation inhibitor, 
abatacept; the humanised monoclonal antibody targeting the interleukin-6 receptor, 
tocilizumab; a monoclonal antibody against B-cell-specific CD20 antigen, rituxamab; a fully 
human monoclonal antibody that binds to B-lymphocyte stimulator, belimumab; and a 
monoclonal antibody which binds to α4β1 integrin, a protein on the surface of lymphocytes, 
blocking their union to the endothelial receptor, natalizumab.  
 
These biologic therapies are widely used in patients treated for inflammatory diseases. 
Although the overall infection risk remains a subject of open debate, some studies have 
reported an increased risk of granulomatous and intracellular infections, such as tuberculosis, 
listeriosis and legionellosis 1, 2. The United States Food and Drug Administration (FDA) has 
added risk of these infections as a Boxed Warning for the entire class of TNFα inhibitors.  
 
TNFα is synthesized by macrophages in response to proinflammatory stimuli and acts as a 
central mediator of inflammation and immune regulation. However, TNFα is also important 
in host defence and plays a role in the immune-mediated response to infection because it 
induces the release of cytokines and local chemokines, leading to attraction and stimulation 
of phagocytes, increased T-cell adhesion, and enhanced antigen presentation with recruitment 
and proliferation of T and B cells 3, 4. Furthermore, murine studies found a protective effect of 
TNF in experimental Legionella pneumophila infections 5, 6. Its antigenic components, 
especially, lipopolysaccharide, are a strong stimulus to produce TNFα, which induces a cell-
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mediated immune response. Rats infected with L. pneumophila and treated with antiTNFα 
antagonists showed persistent pneumonitis with a higher bacterial load, more infected 
macrophages and less recruitment of peripheral blood monocytes to the lung compared to 
control rats5, 6.  
 
Given the theoretic increased risk of legionellosis in patients receiving biologic therapies, we 
aimed to analyse the association between Legionella pneumonia among these patients. Our 
purpose was to characterise the clinical presentation, duration of biologic treatment at onset 
of infection, the use of concomitant immunosuppressive medication and outcomes of the 
Legionella infection cases in patients treated with biologics. 
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MATERIAL AND METHODS  
 
We searched the publicly available Adverse Event Reporting System (AERS) database of the 
FDA for reports of Legionella infections with the use of biologic therapies from 2004 through 
the second quarter of 2011 (30 quarters in total).  AERS is a post-marketing safety database 
composed of spontaneous adverse event reports to the FDA’s Spontaneous Reporting system 
(SRS) before October 1997 and reports to AERS from November 1997 to present. The AERS 
database includes post-marketing adverse events spontaneously reported from US sources 
and attributable post-marketing clinical trial reports from all sources. We also performed a 
PubMed search using the terms “legionella” and “biologics” or “tumour necrosis factor 
antagonists” and included all cases reports in our analysis 1, 7-25. 
 
For our analysis we included the Medical Dictionary for Regulatory Activities (MedDRA) 
term “Legionella infection”. Biologic therapies included etanercept, infliximab, adalimumab, 
golimumab, certolizumab pegol, anakinra, abatacept, tocilizumab, rituximab, belimumab and 
natalizumab. Reports were also examined for concomitant use of immunosuppressive 
medications. FDA AERS reports meeting these criteria were then imported in ASCII format 
into SPSS software (version 20.0, Inc. Chicago, IL) and analytical files were created for the 
final study database, including demographic data, drug characteristics and outcomes. To 
compare cases by biologic drugs, we used the chi-square test with continuity correction for 
categorical variables and the Student t test and Mann-Whitney U-test for continuous 
variables.  
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RESULTS 
 
We found 105 cases of Legionella infection, 68 of which were from FDA AERS. Other data 
were from national registries (19 cases) and isolated case reports (18 cases). The main 
characteristics of the reported cases are described in table 1. Speciation was not denoted in 
the FDA AERS reports. In all other cases in which speciation were performed, the species 
was L. pneumophila (30 cases). 
 
Sixty-one per cent of the patients were males. The median age was 52 years (range 25 to 87 
years). North America and Europe accounted for the bulk of reported cases. France was the 
country which reported the most episodes (27), followed by United States (10), Spain (10), 
Italy (10), the United Kingdom (8), Canada (7) and Germany (6).   
 
Infliximab was the biologic most frequently related to Legionella infection (65.3% of 
reported cases), followed by adalimumab (23.5%), etanercept (5%), rituximab (3%), 
abatacept (1%) and natalizumab (1%). One patient received a combination of adalimumab 
and infliximab. Denominator data is not available so the proportion of patients receiving any 
specific biologic agent was not calculable. The majority of the patients received one or more 
concomitant immunosuppressive drugs, especially corticosteroids (43%), methotrexate 
(35.5%), and azathioprine (13%). Rheumatologic diseases were the most frequent indication 
for administration of biologic therapies (71%). Inflammatory bowel disease patients 
accounted for 16% of the cases and other systemic autoimmune diseases for 7%.  
 
The median duration of biologic therapy prior to onset of Legionella infection was 4 months 
(range from 0.25 to 32 months). This interval was shorter among patients who received 
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infliximab versus those who received etanercept and adalimumab (1 vs. 7.6 months; 
p<0.001). Forty-two percent of all reported cases developed within 90 days of initiating 
biologic treatment. 
 
Three patients were given inappropriate empirical antibiotic treatment in a total of only 8 
patients in whom the initial antibiotic treatment was recorded – two of these three patients 
died 9, 13.    
 
Seventeen deaths were reported from 92 patients in whom outcome was recorded (19%). At 
least 9 survivors required intensive care unit management. 
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DISCUSSION 
 
Our study underlines the relationship between biologics and Legionella infection. This 
relationship was first described in 2006 by Tubach et al 7. They used data from the French 
RATIO registry, designed to collect data on opportunistic and severe infections in patients 
treated with antiTNFα. They described 10 cases of legionellosis among patients with one year 
follow-up, and estimated an incidence of 33-42 cases per 100,000 patients receiving 
biologics, and with a relative risk compared with that for overall population in France 
between 16.5 and 21. The same group recently published a case-control analysis that supports 
these high incidence rates26. In a review of infliximab adverse events reported to the US FDA 
up until 2005, the excess risk of infection was quantified by generating a statistic known as 
the empiric Bayes geometric mean (EBGM) and its corresponding 2-sided 90% confidence 
interval (CI (EB05,EB95) 27. An EB05 value of 8.7 was discovered, implying that the drug-
event pair has been reported 8.7 times as frequently as would be expected if reports involving 
the drug and reports of the event were independent (that is, no association). In contrast, the 
EB05 for tuberculosis was 20.9 27.  
 
Infliximab, which was first approved by the FDA in 2000, was the most commonly reported 
drug related to Legionella infection, followed closely by adalimumab (2002). Only 5 
published cases were associated with etanercept, approved in 1998. More data are needed to 
determine the associated risk of legionellosis in patients receiving newer biologics. It is 
noteworthy that infliximab and adalimumab have a potentially stronger relationship with 
legionellosis than etanercept, in line with the study of Lanternier et al26. Some studies have 
demonstrated higher avidity and better stability of membrane-bound TNF with monoclonal 
antibodies comparing to TNF receptor fusion molecule therapy. Moreover, this difference is 
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also observed regarding other granulomatous and intracellular infections such as tuberculosis, 
which are significantly more frequent in infliximab treated patients compared to etanercept. 
This gives more feasibility to the difference in risk of infection between these drugs.   
 
Significantly, legionellosis mainly occurred in the first six months after initiating treatment 
with biologics.  This interval was also shorter among patients who received infliximab versus 
those who received etanercept and adalimumab (1 vs. 7.6 months, p<0.001). Forty-two 
percent of the cases were reported <90 days after initiating of treatment. These data are in 
line which other studies that reported a decline in the infection risk over time in patients 
treated with biologics. Interestingly, Strangfeld et al analysed the RABBIT German biologic 
register and found that approximately one-third of the decrease in risk was caused by 
improvement in the clinical status and reduction of concomitant steroid therapy and the other 
two-thirds could be explained by selective switching of patients who were at increased risk of 
infection 28. 
 
The fact that most of the analysed cases received other immunosuppressive therapies 
concomitantly is remarkable. There are certainly other reports that describe legionellosis in 
immunosupressed patients who have not received biologic therapies 29-32. Interestingly, 
systemic corticosteroids were extensively used among these patients in similar proportions to 
that in our study, suggesting that it might have played a role in the infection. Furthermore, 
these studies described a high case fatality rate, ranging from 14.3% in solid organ transplant 
recipients to 31% in cancer patients, in concordance with our study which reported a 
mortality of 19%. These rates differ from the ones reported from community-acquired cases 
in non immunosupressed patients which are between 2.5- 6%33, 34.  
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It would have been interesting to know how many cases received inappropriate empirical 
antibiotic treatment and how long it took to get the diagnosis - and if delays were associated 
with increased mortality. In our analysis, only 8 cases had this kind of information and 3 of 
these patients received inappropriate empirical antibiotic therapy, resulting in 2 deaths. 
Although we do not have enough data to draw conclusions, one of the factors that could 
contribute our high mortality rate is a delay in diagnosis and consequently in adequate 
antibiotic treatment.  
 
Legionella infection usually occurs through inhalation of contaminated aerosols produced by 
water systems such as cooling waters, showers, hot water distribution systems and faucets, 
casing sometimes community-acquired outbreaks. The clinical manifestations of 
Legionnaires’ disease do not differ much from other types of pneumonia. Diagnosis depends 
on special laboratory tests, such as the rapid Legionella urinary antigen test, with a sensitivity 
of 0.74 and specificity of 0.9935. Nevertheless, it only detects L. pneumophila serogroup 1. 
Definitive diagnosis is based on cultures of the microorganism from respiratory secretions or 
pleural fluid. The utility of serology is limited, except for retrospectively proving that an 
infection has occurred.  
 
Our study has some limitations. First of all, the voluntary nature of physician reports to the 
FDA AERS may underestimate the real incidence of legionellosis. Secondly, some reports 
may have been registered in the FDA AERS database and also published or included in 
national registries, therefore resulting in duplicate information. For example, France was the 
country that reported most cases, almost 3-fold comparing to United States, Spain and Italy, 
which were the next countries in order of frequency. It is possible this incidence could be 
overestimated if some of the cases were reported twice. Furthermore, some information about 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
11 
 
case reports is lacking and therefore there is limited statistical power and denominator data is 
not available so the proportion of patients receiving any specific biologic agent was not 
calculable.  
Finally we conclude that as biologic therapies are increasingly used to treat some 
inflammatory diseases we should be aware that they may increase susceptibility to cause 
certain infections such as Legionella pneumonia. The highest risk appears to be in patients 
treated with infliximab or adalimumab given concomitantly with other immunosuppressive 
medications during their first months of treatment. A high index of suspicion must be 
maintained if this is considered a potential cause for the patient’s clinical presentation and a 
urinary antigen test should be collected as soon as possible. Rapid diagnosis and treatment is 
mandatory because the presentation of legionellosis in immunocompromised patients can be 
fulminant and severe.   
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Table 1: Main characteristics of the reported cases 
Study name Type of 
study 
Number 
of pts 
with 
infection 
Associated 
disease 
Biologic drug Median 
age 
(range) 
Concomitant 
immunosuppress
ive drugs 
Diagnostic 
method 
Treatment 
duration* 
(median, 
range) 
Outcomes 
FDA AERS 36 Voluntary 
registry 
68 49 
rheumatologi
c diseases, 9 
IBD, 10 
other. 
Infliximab (47), 
adalimumab 
(14), etanercept 
(3), rituximab 
(2), natalizumab 
(1) 
52 (25-85) Steroids (21), MTX 
(22), AZA (5), other 
(5) 
NR 4.6 months 
(<1-30) 
11 deaths 
Tubach7 French 
registry 
(RATIO)  
10 1IBD, 9 
rheumatologi
c diseases 
Adalimumab (6) 
Etanercept(2) 
Infliximab(2) 
51 (40-69) Steroids (8) 
MTX(6) 
9 LAg, 1 
seroconversio
n,2 cultures. 
38.5 weeks 
(3-73) 
3 required 
ICU, all 
recovered 
Perez-Sola8 Spanish 
registry(BIOD
ABASER) 
,including 
6969 pts 
5 Rheumatic 
diseases 
Infliximab, 
Etanercept, 
adalimumab 
NR NR NR 28 months 1 death 
Hofmann9 Case report 2 IBD infliximab 42.5 (26-
59) 
Steroids (2/2) 2 LAg 4 weeks Both 
required 
ICU, 1 died. 
Ramos-Casals10 Registry, 
including 
1370 pts 
1 Systemic 
autoimmune 
diseases 
infliximab NR NR NR NR NR 
Beigel11 Case report 1 IBD infliximab 58 Steroids, AZA LAg, PCR NR ICU. 
Recovery 
Kohn37 Case report 1 IBD infliximab 27 Steroids, AZA PCR 11 days Died from a 
septic shock 
Dixon1 British 
registry 
(BSRBR) 
including 
9868 pts 
2 RA infliximab 54 NR NR 72 weeks NR 
Eisendle13 Case report 1 Erytrodermic 
psoriasis 
infliximab 56 Steroids Cultures 
(post mortem 
2 weeks Died  
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diagnosis) 
Li Gobbi14 Case report 1 RA infliximab 38 MTX LAg 2 weeks recovered 
Mancini15 Case report 1 Behcet’s 
disease 
infliximab 30 MTX NR 4 weeks recovered 
Albert38 Case report 1 RA infliximab 73 Steroids, MTX Culture 13 months recovered 
Wondergem16 Case report 1 RA infliximab 43 Steroids, AZA LAg 3 weeks recovered 
Jinno17 Case report 1 RA adalimumab 67 Steroids, AZA LAg 2 years ICU, 
recovered 
Wuerz39 Case report 1 RA adalimumab 62 AZA LAg, cultures 10 weeks ICU, 
recovered 
Favalli 40 LOHREN 
registry, 
including 
1064 pts 
1 RA AntiTNFα NR NR NR NR NR 
Kaku12 Case report 1 RA adalimumab 65 MTX LAg 2 years Died 
Epping18 Case report 1 Crohn’s 
disease 
Anti TNFα 26 Steroids LAg 16 months recovered 
Aringer19 Case report 1 SLE Rituximab and 
infliximab 
NR Steroids, AZA, 
MMF, 
cyclophosphamide 
NR 8 weeks 
(infliximab) 
Died 
Kroesen20 Retrospective 
study 
1 Psoriasis infliximab 49 MTX LAg NR recovered 
Vinter 41 Case report 2 Crohn’s 
disease  and 
Psoriasis 
infliximab 53.5 NR LAg, PCR 4.5 years 1 died 
Novas42 Case report 1 RA abatacept 73 Steroids, MTX LAg 3 weeks recovered 
*Treatment duration: median duration of biologic therapy prior to onset of Legionella infection. LAg: Legionella antigen in the urine. NR: no reported. IBD: inflammatory 
bowel disease. MTX: methotrexate. AZA: azathioprine. MMF: mycophenolate. RA: rheumatoid arthritis. AntiTNFα: tumor necrosis alpha antagonists. SLE: systemic 
erythematosus lupus.  
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